PDCT-19. A SAFETY STUDY OF VEMURAFENIB, AN ORAL INHIBITOR OF BRAF(V600E), IN CHILDREN WITH RECURRENT/REFRACTORY BRAF(V600E) MUTANT BRAIN TUMORS: PNOC-002

BACKGROUND: Vemurafenib is an orally available, selective ATP-competitive inhibitor of BRAF-V600E kinase, approved in adult metastatic melanoma patients with the V600E mutation. This study was designed to determine the recommended phase 2 dose (RP2D) in patients < 18yrs with BRAF-V600E mutant bra...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Nicolaides, Theo, Nazemi, Kellie, Crawford, John, Kilburn, Lindsay, Minturn, Jane, Gajjar, Amar, Gauvain, Karen, Leary, Sarah, Dhall, Girish, Aboian, Mariam, Robinson, Giles, Molinaro, Annette, Mueller, Sabine, Prados, Michael
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2017
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692489/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.761
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars